Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

MIF-1 (Pro-Leu-Gly-NH₂)

Melanostatin · Pro-Leu-Gly-NH2 · PLG

Animal replicated

Research chemicalTripeptide Dopaminergic Modulator Oxytocin Fragment

RouteInjectableGray-market only

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: Melanostatin — Oxytocin C-Terminal Tripeptide — D2/D4 Allosteric Modulator — Dopaminergic Support — Limitless — Tripeptide, Dopaminergic Modulator, Oxytocin Fragment.
Why people use it: Used primarily for cognitive support and sleep and recovery.

If you only read one thing

MIF-1 is the compound with one of the most interesting pharmacological profiles in this reference — an oxytocin fragment that acts as a dopamine receptor sensitizer, an opioid antagonist, and a mood-relevant brain activator, with remarkable plasma stability that makes systemic delivery feasible — and it has been essentially ignored by Western pharmacology for 30 years. The early clinical signals in Parkinson's and depression were not conclusively negative; they were inconclusive because the research stopped. The community now accesses it through Limitless for dopaminergic support and mood, often unaware that the compound was once studied for Parkinson's disease in Eastern European clinics. This chapter attempts to reconstruct what is known about MIF-1 and be honest about how much has never been resolved.

Check interactions →

Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit

Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat

Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor

Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot

See route notes

Evidence varies by use case

Published literature

0human trials2human studies4animal2in vitro

Human evidence is limited to early open-label/clinical observations in Parkinsonism and mood contexts; no modern randomized controlled trial, Phase 1 PK study, or depression RCT validates MIF-1.

Evidence reality check

Human evidence

2 human studies

2 observational; RCT evidence not present in corpus.

Preclinical base

6 lab signals

4 animal; 2 in-vitro/mechanistic.

Risk posture

No major flags listed

Review route-specific cautions before use.

Categories

Cognition & Mood Sleep & Recovery

Properties

✓ Human evidenceInjectable: extrapolated

Half-life

The dosing frequency for MIF-1 based on this half-life would theoretically be very low — perhaps once every 2-5 days rather than daily

Evidence

CAnimal replicated

THE CRITICAL NAMING CONFUSION

MIF-1 ≠ MIF. MIF-1 (this compound; Pro-Leu-Gly-NH₂; MW 284 Da) is a tripeptide neuropeptide fragment of oxytocin with dopaminergic properties. MIF (Macrophage Migration Inhibitory Factor) is a completely different protein — a cytokine/enzyme involved in immune and inflammatory responses; MW ~12,500 Da; unrelated to this compound in structure, mechanism, or pharmacology. These two compounds share an abbreviation and nothing else. Any literature on 'MIF' in immune or inflammatory contexts is about a different molecule.

Primary Mechanism

D2 and D4 dopamine receptor positive allosteric modulation: MIF-1 binds to an allosteric site on D2 and D4 receptors (not the dopamine binding site) and increases the receptor's sensitivity to dopamine. This is not direct dopamine agonism — MIF-1 does not activate D2 receptors in the absence of dopamine; it makes the receptor more responsive when dopamine is present. Opioid receptor antagonism: blocks morphine-induced catalepsy and some opioid analgesic effects. Inhibits α-MSH release from the pituitary. Potentiates melatonin activity. c-Fos activation in mood, anxiety, memory brain regions.

The Remarkable Plasma Stability

In human plasma at 37°C, MIF-1 requires approximately 5 days for 50% degradation — an extraordinary stability for a tripeptide. Most tripeptides are rapidly cleaved by plasma peptidases within minutes to hours. Khan et al. (2010) noted this stability as one of the properties making MIF-1 a 'worthwhile candidate as a human therapeutic agent.' The C-terminal amide (glycinamide) contributes to this stability by protecting against carboxypeptidase attack. This plasma stability is what makes systemic injection pharmacologically meaningful despite the small peptide size.

The Soviet Research History

MIF-1 was studied extensively by Soviet/Eastern European researchers from the 1970s through the early 1990s for Parkinson's disease and depression. Multiple small clinical studies, case series, and open-label trials were conducted — primarily in Russian-language publications, with some reports appearing in Chinese psychiatric literature. The research largely ceased with the dissolution of the Soviet Union. By the time Western research groups re-investigated MIF-1 (Khan et al. 2010 at Pennington Biomedical), the compound had been essentially abandoned for over a decade despite its positive early signals.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

Pinealon

Same class · Tripeptide

Short Khavinson tripeptide positioned for brain and pineal-gland bioregulation. The appeal is cognitive aging, neuroprotection, and circadian support; the limitation is that the evidence is mostly single-institution preclinical work, not human clinical validation.

DSIP

Shared goal · cognition

Isolated 1977. Named for Sleep. 40+ Years of Research. No Gene Found. No Specific Receptor Identified. Half-Life 15 Minutes In Vitro — Yet Produces Multi-Night Effects. Studied for Sleep, Stress, Alcohol Withdrawal, Opiate Withdrawal, Neuroprotection, and Longevity. The Most Mechanistically Mysterious Compound in this reference.

Epitalon